PepGen Inc. reports results for the quarter ended June 30 - Earnings Summary
PepGen Q2 net loss narrows as expenses fall
Brief: PepGen Q2 EPS USD -0.26
PepGen Inc expected to post a loss of 29 cents a share - Earnings Preview
Brief: PepGen Files To Offer Up To $400 Mln In Securities From Time To Time
PepGen Q1 loss narrows as operating expenses fall
Brief: PepGen Q1 EPS USD -0.26
NASDAQ RESUMED AT 04:40 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
PepGen falls after US FDA puts partial hold on mid‑stage drug trial
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
Biotech firm PepGen's Q4 net loss narrows
NASDAQ RESUMED AT 04:30 PM
Brief: Pepgen Inc - U.S. FDA Places FREEDOM2 Trial On Partial Clinical Hold Related To Preclinical Pharmacology And Toxicology
Brief: PepGen Q4 EPS USD -0.27
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:01 PM
Brief: PepGen Appoints Joseph Vittiglio, Esq., As Chief Business And Legal Officer
Brief: PepGen Announces Issuance of US Patent for Proprietary PGN-EDODM1 Molecule
Biotech firm PepGen's Q3 net loss narrows to $18 mln